A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
NCT00747318
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
280
Enrollment
INDUSTRY
Sponsor class
Conditions
Asthma
Interventions
DRUG:
SKP FlutiForm HFA pMDI
Sponsor
SkyePharma AG
Collaborators
[object Object]